Status:
TERMINATED
Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study
Lead Sponsor:
University of Wisconsin, Madison
Collaborating Sponsors:
United Therapeutics
Conditions:
Pulmonary Arterial Hypertension
Right-Sided Heart Failure
Eligibility:
All Genders
18-75 years
Brief Summary
Pulmonary arterial hypertension(PAH) is associated with the development of right heart failure. In the setting of heart failure, the heart shifts to increasing dependence on glucose metabolism. In thi...
Detailed Description
Pulmonary arterial hypertension is associated with the development of right heart failure. In the setting of heart failure, the heart shifts to increasing dependence on glucose metabolism. In this stu...
Eligibility Criteria
Inclusion
- World Health Organization(WHO) group PAH secondary into idiopathic pulmonary arterial hypertension(IPAH) or connective tissue disease associated pulmonary arterial hypertension (CTDPAH)
- New York Heart Association (NYHA) classification I - III heart failure
- Vasodilator therapy naive
- Able to provide informed consent
Exclusion
- Metabolic disorders such as uncontrolled diabetes (A1c \> 8%) that may interfere with FDG uptake
- Baseline 6-minute walk distance (6MWD) \< 400 feet or NYHA class IV heart failure
- Musculoskeletal abnormalities that would prevent exercise
- Contraindications to MRI
Key Trial Info
Start Date :
November 14 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 21 2020
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04090866
Start Date
November 14 2019
End Date
July 21 2020
Last Update
July 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin-Madison
Madison, Wisconsin, United States, 53792